$2.1 Billion is the total value of Redmile Group, LLC's 68 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AUGX | AUGMEDIX INC | $80,496,184 | +7.1% | 15,630,327 | 0.0% | 3.83% | +32.7% | |
| LIVN | LIVANOVA PLC | $58,194,017 | +2.8% | 1,100,492 | 0.0% | 2.77% | +27.5% | |
| PLRX | PLIANT THERAPEUTICS INC | $46,438,237 | -4.3% | 2,678,099 | 0.0% | 2.21% | +18.6% | |
| ZYMEWORKS INC | $35,892,198 | -26.6% | 5,661,230 | 0.0% | 1.71% | -9.0% | ||
| FATE | FATE THERAPEUTICS INC | $27,823,785 | -55.5% | 13,124,427 | 0.0% | 1.32% | -44.8% | |
| KYMR | KYMERA THERAPEUTICS INC | $25,972,247 | -39.5% | 1,868,507 | 0.0% | 1.24% | -25.0% | |
| IGMS | IGM BIOSCIENCES INC | $24,812,376 | -9.5% | 2,971,542 | 0.0% | 1.18% | +12.2% | |
| COGT | COGENT BIOSCIENCES INC | $20,019,997 | -17.7% | 2,053,333 | 0.0% | 0.95% | +2.1% | |
| PRIME MEDICINE INC | $12,634,299 | -34.9% | 1,324,350 | 0.0% | 0.60% | -19.3% | ||
| ETNB | 89BIO INC | $11,764,585 | -18.5% | 761,955 | 0.0% | 0.56% | +1.1% | |
| ABSCI CORPORATION | $10,601,044 | -13.2% | 8,031,094 | 0.0% | 0.50% | +7.5% | ||
| STTK | SHATTUCK LABS INC | $8,542,269 | -51.3% | 5,619,914 | 0.0% | 0.41% | -39.7% | |
| ANNX | ANNEXON INC | $8,267,528 | -33.0% | 3,503,190 | 0.0% | 0.39% | -16.9% | |
| SCIENCE 37 HOLDINGS INC | $7,923,294 | +88.2% | 19,808,234 | 0.0% | 0.38% | +132.7% | ||
| ALXO | ALX ONCOLOGY HLDGS INC | $6,159,787 | -36.1% | 1,283,289 | 0.0% | 0.29% | -20.8% | |
| ALVR | ALLOVIR INC | $4,102,133 | -36.8% | 1,907,969 | 0.0% | 0.20% | -21.7% | |
| NUVB | NUVATION BIO INC | $4,061,552 | -25.6% | 3,031,009 | 0.0% | 0.19% | -7.7% | |
| LVTX | LAVA THERAPEUTICS NV | $3,090,814 | -26.6% | 2,074,372 | 0.0% | 0.15% | -9.3% | |
| INVIVYD INC | $2,449,233 | +61.9% | 1,440,725 | 0.0% | 0.12% | +101.7% | ||
| XERIS BIOPHARMA HOLDINGS INC | $1,946,652 | -29.0% | 1,046,587 | 0.0% | 0.09% | -11.4% | ||
| ACHL | ACHILLES THERAPEUTICS PLCsponsored ads | $1,463,200 | -3.7% | 1,608,089 | 0.0% | 0.07% | +20.7% | |
| NVTA | INVITAE CORP | $1,380,100 | -46.4% | 2,280,403 | 0.0% | 0.07% | -33.3% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $558,173 | -15.7% | 715,607 | 0.0% | 0.03% | +8.0% | |
| BCEL | ATRECA INC | $115,532 | -73.4% | 442,653 | 0.0% | 0.01% | -70.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.